---

title: "Abnormal T-Cell activation and cytotoxic T-Cell frequency discriminate symptom severity in myalgic encephalomyelitis/chronic fatigue syndrome."
tags:
- ðŸ§ª Biomarker
created: '2025-12-10'
published: '2025-12-10'

---


<details>
<summary>Lee et al. (2025)</summary>

- **Authors:** Ji-Sook Lee, Eliana Lacerda, Caroline Kingdon, Ella Abken, Giada Susannini, Hazel M. Dockrell, Luis Nacul, Jacqueline M. Cliff.
- **Institutes:** Department of Infection Biology, London School of Hygiene & Tropical Medicine; Clinical Research Department, London School of Hygiene & Tropical Medicine; Centre for Inflammation Research and Translational Medicine, Brunel University London; Division of Biosciences, Department of Life Sciences, Brunel University London.
- **Publisher:** Journal of Translational Medicine
- **Link:** [DOI](https://doi.org/10.1186/s12967-025-07507-x)

</details>


## Summary

This research is significant because it provides objective biological evidence that ME/CFS is not a uniform condition, but rather one that may involve different immune system "stages" or drivers depending on the person's level of disability. By showing that severe patients have a distinct inflammatory signature compared to those with milder symptoms, the study opens the door for "stratified medicine," where treatments could be specifically targeted to a patient's immune profile. This could eventually lead to the development of a blood-based test that not only helps diagnose the condition but also helps doctors monitor how a patient is faring over time. While these results are promising, they represent an early step toward a validated diagnostic marker and require more extensive testing before they can be used in routine clinical practice.

## What was researched?

This study investigated whether specific immunological markers in the blood could distinguish between different levels of disease severity in individuals with ME/CFS. Specifically, researchers used flow cytometry to examine the activation and characteristics of "killer" immune cellsâ€”including CD8+ T cells, Natural Killer (NK) cells, and Mucosal-Associated Invariant T (MAIT) cellsâ€”to see if their profiles differed between mild/moderate and severe cases.

## Why was it researched?

ME/CFS is a complex disease where patients often experience varying degrees of disability, yet the biological reasons for these differences in severity are not well understood. While previous studies have identified immune system abnormalities, there has been a lack of clarity regarding whether specific immune signatures correlate with how severely a patient is affected. Identifying these differences is critical for developing better diagnostic tools and tailoring treatments to individual patient needs.

## How was it researched?

The researchers conducted an immunological analysis of blood samples from a cohort of 96 people living with ME/CFS, categorized into two groups: mild/moderate (n = 43) and severe (n = 53). Using flow cytometry, they measured various cellular markers of activation (such as CD69 and CD38), exhaustion, and "immunosenescence" (cell aging). They also stimulated the cells in a laboratory setting to observe the production of pro-inflammatory cytokines like interferon-Î³, tumor necrosis factor (TNF), and interleukin-17. Statistical analyses were then performed to determine which immune features best discriminated between the two severity groups.

## What has been found?

The study found distinct immune "fingerprints" for different severity levels: patients with mild/moderate ME/CFS showed signs of "early-immunosenescence" (CD28-CD57- cells), which often indicates a response to a persistent viral infection. In contrast, patients with severe ME/CFS exhibited much higher levels of activated lymphocytes and a significantly greater production of pro-inflammatory cytokines, suggesting a state of chronic, non-specific inflammation. These findings were consistent across several types of cytotoxic cells, and a combination of these markers was able to distinguish between the two patient groups with high statistical significance (AUC of 0.7843).

## Discussion

The authors note that the observed differences suggest that the underlying disease processes may shift as ME/CFS becomes more severe. They highlight that the markers identified have strong potential for use in clinical stratificationâ€”meaning they could help doctors categorize patients more accurately. A primary limitation mentioned is the need for further validation in larger, longitudinal studies that include healthy control groups to confirm if these signatures are unique to ME/CFS.

## Conclusion & Future Work

The authors conclude that symptom severity in ME/CFS is mirrored by specific, measurable changes in the immune system, particularly regarding how T cells and NK cells are activated. They suggest that the disease might involve different pathological mechanismsâ€”such as viral persistence in milder cases versus chronic inflammation in severe cases. Future research will focus on verifying these markers in larger patient populations and investigating whether they can be used as prognostic tools to predict disease progression.
